Gliknik Inc., a biopharmaceutical company based at the University of Maryland's BioPark in downtown Baltimore, said Monday it had won a $1.5 million contract from the National Cancer Institute to continue development of its cancer-fighting technology.
The grant places the company on a path that could lead to clinical trials in two years, said David S. Block, Gliknik's chief executive.
Since its formation in 2007, Gliknik has raised $10 million from investors, largely with the help of Maryland's biotechnology tax credit. The company also has attracted $2.5 million in nonequity financing from government sources, including the grant from the National Cancer Institute.
Twitter.com/gussent